Director/PDMR Shareholding replacement

RNS Number : 1726D

GlaxoSmithKline PLC

24 April 2017

 

The following amendment has been made to the Director/PDMR Shareholding announcement released on 19 April 2017 at 13:27 (BST) under RNS No 7391C.

Removal of the text which incorrectly reported that 13.866 Ordinary Shares had been acquired following the re-investment of dividends paid to shareholders on 13 April 2017 on released shares from the Company's 2009 Deferred Annual Bonus Plan on a post-tax basis - Matching Award.

All other details remain unchanged.

The full amended text is shown below.

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms C Thomas
b)	Position/status	SVP, HR
c)	Initial notification/ amendment	Amendment
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on released shares from the Company's 2009 Deferred Annual Bonus Plan on a post-tax basis - Co-investment shares.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.4042 41.365 (Co-investment shares)
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction	2017-04-18
f)	Place of the transaction	London Stock Exchange (XLON)

 

END

 

 

DSHKMGZDKDMGNZM